The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010

Table 3 Baseline characteristics of HCV infection of patients included in the ANRS CO 13 HEPAVIH cohort of HIV-HCV co-infected patients, France, 2006-2008

	Total N=1175	HCV chronically infected patients N=1048	Sustained HCV responders N=127
Years since HCV diagnosis, median (IQR)	-	10 (6-14)	-
HCV genotype, N (%)	-		-
1		577 (56.0)
2		39 (3.8)
3		187 (18.1)
4		225 (21.8)
5 or other		3 (0.3)
HCV plasma RNA (Log₁₀) (IU/ML), median (IQR)	-	6.2 (5.7-6.5)	-
Past anti HCV therapy, N (%)
Interferon alone	40 (3.4)	33 (3.1)	7 (5.5)
Interferon+ ribavirin	93 (7.9)	65 (6.2)	28 (22)
Pegylated interferon plus ribavirin	365 (31.1)	273 (26.0)	92 (72.5)
Cirrhosis*, N (%)	255 (25.2)	229 (25.0)	26 (26.8)
Documented decompensated liver disease, N (%)	32 (2.7)	27 (2.6)	5 (3.9)

ISSN: 1471-2334